AQR Capital Management LLC Acquires 3,307 Shares of Cencora, Inc. (NYSE:COR)

AQR Capital Management LLC lifted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 0.2% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,464,466 shares of the company's stock after buying an additional 3,307 shares during the period. Cencora makes up approximately 0.4% of AQR Capital Management LLC's portfolio, making the stock its 28th biggest holding. AQR Capital Management LLC owned 0.76% of Cencora worth $329,036,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of COR. JFS Wealth Advisors LLC grew its stake in Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in Cencora in the 4th quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC boosted its stake in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Kentucky Trust Co bought a new position in shares of Cencora during the fourth quarter valued at about $33,000. Finally, WASHINGTON TRUST Co grew its position in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Activity at Cencora

In other news, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the sale, the chief executive officer now directly owns 47,582 shares in the company, valued at approximately $13,766,900.06. This trade represents a 9.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now owns 317,913 shares of the company's stock, valued at $85,680,732.63. The trade was a 4.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,223 shares of company stock valued at $13,580,967 over the last 90 days. 10.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. UBS Group raised their target price on Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. JPMorgan Chase & Co. boosted their price target on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Finally, Wells Fargo & Company increased their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Cencora currently has an average rating of "Moderate Buy" and an average price target of $290.00.

Cencora Stock Performance

Cencora stock traded up $1.74 during midday trading on Friday, hitting $292.17. The stock had a trading volume of 1,046,574 shares, compared to its average volume of 1,511,470. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $296.65. The company has a market capitalization of $56.66 billion, a PE ratio of 41.56, a P/E/G ratio of 1.31 and a beta of 0.55. The firm's fifty day moving average is $271.82 and its two-hundred day moving average is $251.02.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's payout ratio is 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.